Literature DB >> 12062593

Analysis of repeat stereotactic radiosurgery for progressive primary and metastatic CNS tumors.

Ajay Bhatnagar1, Dwight E Heron, Douglas Kondziolka, L Dade Lunsford, John C Flickinger.   

Abstract

PURPOSE: To identify and evaluate the pretreatment and patient factors that would predict for complications after repeat radiosurgery. METHODS AND MATERIALS: The data from 26 patients who underwent re-irradiation with Gamma Knife surgery after a previous procedure in the same or subjacent location were available for evaluation. The range of follow-up was 1-45 months (mean 10). The mean minimal and maximal initial dose and volume for all 26 patients was 16.2 Gy (range 12-22), 31.0 Gy (range 22.2-40.0), and 12.4 cm(3) (range 1.20-70.84), respectively. The mean marginal and maximal repeated radiosurgery dose and volume for all 26 patients was 14.9 Gy (range 12-22.5), 29.7 Gy (range 18.0-45.0) and 12.8 cm(3) (range 1.10-39.20), respectively.
RESULTS: Tumor control was significantly better statistically (p = 0.0129) for benign tumors (6 of 6, 100% actuarial rate at 4 years) compared with malignant tumors (7 of 20, 35% actuarial rate at 3 years, 3 of 4 metastatic tumors and 2 of 10 primary malignant gliomas). The retreatment volume for radiosurgery correlated significantly with the probability of neurologic decline (any cause) (p = 0.0181).
CONCLUSION: Repeat radiosurgery can be performed for recurrent tumors with minimal central nervous system toxicity, especially for benign tumors, with reasonable tumor control.

Entities:  

Mesh:

Year:  2002        PMID: 12062593     DOI: 10.1016/s0360-3016(02)02784-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery.

Authors:  Eisuke Abe; Hidefumi Aoyama
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 2.  Radiosurgery for metastatic brain tumors.

Authors:  Toru Serizawa
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

3.  Tumor control and incidence of radiation necrosis after reirradiation with stereotactic radiosurgery for brain metastases.

Authors:  Breanne E Terakedis; Randy L Jensen; Kenneth Boucher; Dennis C Shrieve
Journal:  J Radiosurg SBRT       Date:  2014

4.  Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis.

Authors:  Douglas Emerson Holt; Beant Singh Gill; David Anthony Clump; Jonathan E Leeman; Steven A Burton; Nduka M Amankulor; Johnathan Anderson Engh; Dwight E Heron
Journal:  Front Oncol       Date:  2015-04-08       Impact factor: 6.244

Review 5.  Methods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer.

Authors:  Anna Patla; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Jerzy Władysław Mituś; Anna Mucha-Małecka; Marian Reinfuss
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

6.  Repeated Stereotactic Radiosurgery in Brain Metastases: A Case Report.

Authors:  Elena Configliacco; Liliana Belgioia; Salvina Barra; Flavio Giannelli; Stefano Agostinelli; Renzo Corvò
Journal:  Cureus       Date:  2017-12-30

7.  Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation: diagnostic contribution, functional outcome, and prognostic factors.

Authors:  Koichi Mitsuya; Yoko Nakasu; Nakamasa Hayashi; Shoichi Deguchi; Takuma Oishi; Takashi Sugino; Kazuaki Yasui; Hirofumi Ogawa; Tsuyoshi Onoe; Hirofumi Asakura; Hideyuki Harada
Journal:  BMC Cancer       Date:  2020-04-17       Impact factor: 4.430

8.  Repeat stereotactic radiosurgery in the management of brain metastases from NSCLC: A case report and review of the literature.

Authors:  Giulia Marvaso; Agnese Barone; Caterina Vaccaro; Vicente Bruzzaniti; Silvia Grespi; Valerio Scotti; Cataldo Bianco
Journal:  Oncol Lett       Date:  2013-08-02       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.